Vaxcyte logo
Vaxcyte
PCVX | NASDAQ
Chart Builder DCF Calculator
$61.61
-$1.76 (-2.78%)
At close: Nov 16, 2026, 4:00 PM ET
$61.61
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Vaxcyte Company Profile

Company profile explained

Company Profile

Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.

Key Executives

Name Position
Grant E. Pickering Co-Founder, Chief Executive Officer & Director
Andrew L. Guggenhime President & Chief Financial Officer
David McAvoy Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Whitney Jones Chief People Officer
Elvia Cowan Senior VP of Finance & Chief Accounting Officer
Harp Dhaliwal Chief Technical Operations Officer
James Wassil Executive VP, Chief Scientific Officer & COO
Janet Graesser Senior Vice President of Corporate Affairs
Jeff Fairman Co-Founder & Vice President of Research
Jeff Macdonald Executive Director of Investor Relations
Mikhail Eydelman Senior VP & General Counsel

Latest SEC Filings

Date Type Title
Oct 09, 2026 8-K Current Report
Oct 08, 2026 424B5 Filing
Oct 08, 2026 424B5 Filing
Oct 07, 2026 4 Filing
Oct 07, 2026 4 Filing
Oct 07, 2026 FWP Filing
Oct 06, 2026 305B2 Filing
Oct 06, 2026 424B5 Filing
Oct 06, 2026 424B5 Filing
Oct 05, 2026 8-K Current Report
View All SEC Filings ➞
Vaxcyte
Vaxcyte logo
Country United States
IPO Date Jun 12, 2020
Industry Biotechnology
Sector Healthcare
Employees 507
CEO Grant E. Pickering

Contact Details

825 Industrial Road San Carlos, California 94070 United States

Stock Details

Ticker Symbol PCVX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001649094
CUSIP Number 92243G108
ISIN Number US92243G1085
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.